Sirtris, a Cambridge, MA, unit of London-based drug giant GlaxoSmithKline (NYSE:[[ticker:GSK]]), says that George Vlasuk has been named president and head of Sirtris. Vlasuk, who was previously vice president of metabolic and hemophilia in the pharmaceutical division of Madison, NJ-based Wyeth (NYSE:[[ticker:WYE]]), will report to Sirtris CEO Christoph Westphal. Vlasuk will be based in Cambridge and be responsible for all research, development, and operations at Sirtris, which is developing treatments for diseases of aging such as Type 2 diabetes.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
